A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.

A Twin Cities teenager is facing an unimaginable battle: terminal cancer. She's fortunate enough to have family by her side ...

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global ...

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed ...

Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...

Classy move by the Tigers, honoring late sportswriter Pat Caputo with a moment of silence Friday night at Comerica Park.

The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both ...

Cancer survivor Susan Steer, who is in her 70s, is calling on people across Mayo to come along to Relay For Life Mayo at its ...

Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy ...

The “Nobody Wants This” star learned she was a carrier for the BRCA gene, a genetic mutation known for an increased risk of ...

Investigators assessed whether a concurrent radiation boost during whole breast irradiation is noninferior to sequenential boost for safety, cosmesis, and ipsilateral recurrence for patients with high ...

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human ...